{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:05:24Z","timestamp":1781111124852,"version":"3.54.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Aneurysmal subarachnoid hemorrhage (SAH) carries a high risk of early rebleeding and worsens prognosis. Tranexamic acid (TXA), an antifibrinolytic agent, can prevent rebleeding; however, its effects on mortality and neurological outcomes remain controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review evaluated the efficacy and safety of TXA with SAH. MEDLINE, CENTRAL, EMBASE, ICTRP, and ClinicalTrials.gov were systematically searched for randomized controlled trials (RCTs) and non-randomized studies of interventions (NRSIs) to assess TXA use in SAH. Studies comparing TXA with controls with SAH were included. The primary outcome was the mortality; secondary outcomes included neurological outcomes, rebleeding, thromboembolism, delayed cerebral ischemia (DCI), hydrocephalus, and adverse events. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen RCTs (3,109 patients) and nine NRSIs (1,506 patients) were included. RCTs demonstrated that TXA likely does not reduce mortality (risk ratio [RR], 1.00; 95% confidence interval [CI], 0.82\u20131.22; moderate certainty) and neurological outcome, and may not increase thromboembolism and DCI. However, TXA probably reduces rebleeding but probably increases hydrocephalus. The NRSIs results were similar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Although routine use is not supported, TXA may be considered for high-risk patients when early aneurysm treatment is unavailable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/osf.io\/yp78b\/<\/jats:uri>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1617817","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T01:28:14Z","timestamp":1750123694000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of tranexamic acid administration for subarachnoid hemorrhage: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Eriya","family":"Imai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takero","family":"Terayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Hifumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jamaneurol.2019.0006","article-title":"Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and Meta-analysis","volume":"76","author":"Etminan","year":"2019","journal-title":"JAMA Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.wneu.2011.03.025","article-title":"Risk factors related to aneurysmal rebleeding","volume":"76","author":"Guo","year":"2011","journal-title":"World Neurosurg"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1212\/wnl.54.1.77","article-title":"Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial","volume":"54","author":"Roos","year":"2000","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ana.410030607","article-title":"Treatment of subarachnoid haemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial","volume":"3","author":"Chandra","year":"1978","journal-title":"Ann Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0140-6736(20)32518-6","article-title":"Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial","volume":"397","author":"Post","year":"2021","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12028-023-01713-5","article-title":"Guidelines for the Neurocritical Care Management of Aneurysmal Subarachnoid Hemorrhage","volume":"39","author":"Treggiari","year":"2023","journal-title":"Neurocrit Care"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00701-020-04673-3","article-title":"Timelines and rebleeds in patients admitted into neurosurgical care for aneurysmal subarachnoid haemorrhage","volume":"163","author":"Sorteberg","year":"2021","journal-title":"Acta Neurochir"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/MBC.0000000000000845","article-title":"No hyperfibrinolysis following subarachnoid or intracerebral haemorrhage: a prospective cohort study","volume":"30","author":"Lauridsen","year":"2019","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"FSO866","DOI":"10.2144\/fsoa-2023-0014","article-title":"The efficacy of antifibrinolytic therapy in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis","volume":"9","author":"Fatima","year":"2023","journal-title":"Future Sci OA"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/00207454.2022.2148957","article-title":"Tranexamic acid for patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis of 2991 patients","volume":"134","author":"Ghaith","year":"2022","journal-title":"Int J Neurosci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"15275","DOI":"10.1038\/s41598-021-94727-y","article-title":"Tranexamic acid in non-traumatic intracranial bleeding: a systematic review and meta-analysis","volume":"11","author":"Bouillon-Minois","year":"2021","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/bmj.n71","article-title":"Statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2020","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"106845","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106845","article-title":"Evidence-based interconversion of the Glasgow outcome and modified Rankin scales: pitfalls and best practices","volume":"31","author":"Gaastra","year":"2022","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"ref17","article-title":"Cochrane handbook for systematic reviews of interventions second edition","volume-title":"Cochrane Database Systematic Review","author":"Higgins","year":"2019"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/jcp.33.Suppl_14.68","article-title":"Tranexamic acid (AMCA) in aneurysmal subarachnoid haemorrhage","volume":"33","author":"Fodstad","year":"1980","journal-title":"J Clin Pathol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1227\/00006123-198102000-00004","article-title":"Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial","volume":"8","author":"Fodstad","year":"1981","journal-title":"Neurosurgery"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/01.STR.10.5.519","article-title":"Tranexamic acid in subarachnoid hemorrhage. A double-blind study","volume":"10","author":"Kaste","year":"1979","journal-title":"Stroke"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJM198408163110703","article-title":"Antifibrinolytic treatment in subarachnoid hemorrhage","volume":"311","author":"Vermeulen","year":"1984","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/01.STR.19.10.1250","article-title":"Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage","volume":"19","author":"Hijdra","year":"1988","journal-title":"Stroke"},{"key":"ref24","first-page":"141","article-title":"The effect of tranexamic acid on bleeding time and haemostasis","volume":"34","author":"Menzies","year":"1991","journal-title":"Neurochirurgia (Stuttg)"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01402177","article-title":"Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms - a double-blind placebo-controlled study","volume":"102","author":"Tsementzis","year":"1990","journal-title":"Acta Neurochir"},{"key":"ref26","first-page":"74","article-title":"Cerebral blood flow in patients with a subarachnoid haemorrhage during treatment with tranexamic acid","volume":"35","author":"Tsementzis","year":"1992","journal-title":"Neurochirurgia (Stuttg)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3171\/jns.2002.97.4.0771","article-title":"Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study","volume":"97","author":"Hillman","year":"2002","journal-title":"J Neurosurg"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ana.410020311","article-title":"Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial","volume":"2","author":"van Rossum","year":"1977","journal-title":"Ann Neurol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/bmj.1.6118.945","article-title":"Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms?","volume":"1","author":"Maurice-Williams","year":"1978","journal-title":"Br Med J"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e0211868","DOI":"10.1371\/journal.pone.0211868","article-title":"Short-term tranexamic acid treatment reduces in-hospital mortality in aneurysmal sub-arachnoid hemorrhage: a multicenter comparison study","volume":"14","author":"Post","year":"2019","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF01400945","article-title":"Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid","volume":"52","author":"Gelmers","year":"1980","journal-title":"Acta Neurochir"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/01.STR.20.12.1674","article-title":"Short-term tranexamic acid treatment in aneurysmal subarachnoid hemorrhage","volume":"20","author":"Wijdicks","year":"1989","journal-title":"Stroke"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12028-023-01732-2","article-title":"Effects of Tranexamic acid in patients with subarachnoid hemorrhage in Brazil: a prospective observational study with propensity score analysis","volume":"39","author":"Rynkowski","year":"2023","journal-title":"Neurocrit Care"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF01402885","article-title":"Rebleeding, ischaemia and hydrocephalus following anti-fibrinolytic treatment for ruptured cerebral aneurysms: a retrospective clinical study","volume":"93","author":"Pinna","year":"1988","journal-title":"Acta Neurochir"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1227\/00006123-198310000-00010","article-title":"Subarachnoid hemorrhage with normal cerebral panangiography","volume":"13","author":"B\u00e9guelin","year":"1983","journal-title":"Neurosurgery"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/pgmj.47.546.199","article-title":"Use of an anti-fibrinolytic agent (tranexamic acid) in the management of ruptured intracranial aneurysms","volume":"47","author":"Gibbs","year":"1971","journal-title":"Postgrad Med J"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3171\/jns.1980.52.4.0453","article-title":"Preoperative treatment of ruptured intracranial aneurysms with tranexamic acid and monitoring of fibrinolytic activity","volume":"52","author":"Alvarez Garijo","year":"1980","journal-title":"J Neurosurg"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/153857448602000102","article-title":"Prevention of early recurrence of aneurysmal subarchnoid haemorrhage by tranexamic acid: a controlled clinical trial","volume":"20","author":"Chowdhary","year":"1986","journal-title":"Vasc Surg"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12028-011-9581-0","article-title":"Rebleeding after aneurysmal subarachnoid hemorrhage","volume":"15","author":"Starke","year":"2011","journal-title":"Neurocrit Care"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e0282726","DOI":"10.1371\/journal.pone.0282726","article-title":"Efficacy and safety of tranexamic acid in intracranial haemorrhage: a meta-analysis","volume":"18","author":"Xiong","year":"2023","journal-title":"PLoS One"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"710495","DOI":"10.3389\/fneur.2021.710495","article-title":"Safety and efficacy of tranexamic acid in aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials","volume":"12","author":"Ren","year":"2021","journal-title":"Front Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"790149","DOI":"10.3389\/fsurg.2021.790149","article-title":"Efficacy and safety of tranexamic acid in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Shi","year":"2021","journal-title":"Front Surg"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3390\/healthcare12232452","article-title":"The effectiveness and safety of Tranexamic acid in treating aneurysmal subarachnoid hemorrhage: a systematic review and Meta-analysis","volume":"12","author":"Al Zayer","year":"2024","journal-title":"Healthc (Basel, Switzerland)"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jss.2024.07.042","article-title":"Tranexamic acid use in the surgical arena: a narrative review","volume":"302","author":"Mergoum","year":"2024","journal-title":"J Surg Res"}],"updated-by":[{"DOI":"10.3389\/fneur.2025.1754088","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000}}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1617817\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:32:26Z","timestamp":1765816346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1617817\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":44,"alternative-id":["10.3389\/fneur.2025.1617817"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1617817","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"article-number":"1617817"}}